EMA (EU)
GUIDANCE FINAL
Draft guideline on the requirements for demonstrating therapeutic equivalence for nasal products
Published: 10/8/2026Detected: 10/8/2026
Summary preview
Defines a stepwise, evidence-based framework for demonstrating therapeutic equivalence for nasal products with the same active moiety(ies), prioritizing in vitro data and using pharmacokinetics as a surrogate for local…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountrespiratory
pediatrics
immunology
#therapeutic equivalence
#nasal products
#bioequivalence
#pharmacokinetics
#systemic safety
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system12/7/2026
- Unified application programming interface (API) platform event12/2/2026
- Committee for Advanced Therapies (CAT): 2-4 December 202612/2/2026
- Committee for Medicinal Products for Veterinary Use (CVMP): 1-3 December 202612/1/2026
- Committee for Orphan Medicinal Products (COMP): 1-3 December 202612/1/2026